Last checked at 26 Feb 2024 08:51
AstraZeneca's Voydeya treatment recommended for EU approval
(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Astrazeneca Share News (AZN)
AZN Share
Price
AZN Share
News
AZN Share
Chat
AZN Share
Trades16,688
AZN
Live RNS
AZN Share
Charts
AZN Level 2
Console
AZN Live
Share Price
AZN Broker
Ratings
AZN Directors
Deals
AZN Financial
Diary
AZN
Fundamentals
AZN Short
Positions
AZN
Media
Astrazeneca Information
Share Price Information for Astrazeneca (AZN)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
12,024.00
Bid:
12,024.00
Ask:
12,028.00
Change:
36.00 (0.30%)
Spread:
4.00 (0.033%)
Open:
12,254.00
High:
12,256.00
Low:
12,018.00
Prev. Close:
11,988.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.EU endorses wider use of AstraZeneca cancer drug
Mon, 29th Apr 2019 07:30
(Sharecast News) - AstraZeneca's ovarian cancer drug Lynparza on Monday received an endorsement from the European Medicines Agency, where a committee approved it to be used as a first-line maintenance treatment.The Committee for Medicinal Products for Human Use (CHMP) recommended the use of the drug specifically in cases of advanced ovarian cancer with a mutation in the BRCA gene following completion of first-line platinum-based chemotherapy.The decision to endorse the treatment followed the Phase III SOLO-1 trial which showed that Lynparza, which is being jointly developed and commercialised by AstraZeneca and Merck, reduced the risk of disease progression or death by 70% against a placebo following response to platinum-based chemotherapy.The drug is currently approved in 64 countries for the maintenance treatment of platinum-sensitive relapsed ovarian cancer regardless of BRCA status, in the US as first-line maintenance treatment of BRCAm advanced ovarian cancer following response to platinum-based chemotherapy, and in 38 countries for germline BRCAm HER2-negative metastatic breast cancer previously treated with chemotherapy.Roy Baynes, senior vice president and head of global clinical development and chief medical officer at Merck's Research Laboratories, said: "If approved, this expanded indication could change the way women in Europe with BRCA-mutated advanced ovarian cancer are treated."
More News
26 Feb 2024 07:22
AstraZeneca's blood-disorder drug recommended for EU approval
(Sharecast News) - European regulators has given the green light to AstraZeneca's blood-disorder drug Voydeya, the biopharma giant announced on Monday.
Read more22 Feb 2024 17:36
EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track"
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and Thursday and not separately reported by Alliance News:
Read more20 Feb 2024 10:29
AstraZeneca acquires US-based biopharmaceutical company
(Sharecast News) - Drugmaker AstraZeneca revealed late on Monday afternoon that it had successfully completed its acquisition of US-based biopharmaceutical company Icosavax.
Read more20 Feb 2024 09:40
LONDON BROKER RATINGS: JPMorgan cuts Airtel Africa price target by 28%
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:
Read more19 Feb 2024 16:51
LONDON MARKET CLOSE: Europe lacks direction on quiet Monday
(Alliance News) - European markets lacked direction on Monday, after a quiet day as the US markets celebrated George Washington's birthday.
Read more19 Feb 2024 15:59
London close: Stocks manage gains on globally quiet day
(Sharecast News) - London's financial markets finished in positive territory on Monday, with stocks closing in the green after overcoming minor losses earlier in the session.
Read more19 Feb 2024 15:39
UPDATE: AstraZeneca completes USD1.1 billion acquisition of Icosavax
(Alliance News) - AstraZeneca PLC on Monday said it has completed the acquisition of Icosavax Inc.
Read more19 Feb 2024 11:51
LONDON MARKET MIDDAY: Stocks lack direction amid quiet start to week
(Alliance News) - Stock prices in London lacked direction at midday Monday, amid a quiet start to the week.
Read more19 Feb 2024 08:44
LONDON MARKET OPEN: Stocks drift; Currys surges on takeover interest
(Alliance News) - Stock prices in London were looking for direction early Monday, as investors weighed possible trajectories for US interest rate cuts and a China's economic recovery.
Read more19 Feb 2024 08:36
TOP NEWS: AstraZeneca celebrates Tagrisso approval and new data
(Alliance News) - AstraZeneca PLC on Monday announced new study data and a new approval for its cancer medication Tagrisso.
Read more19 Feb 2024 08:03
AstraZeneca's Tagrisso gains FDA approval
(Sharecast News) - Drugmaker AstraZeneca traded higher early on Monday after revealing that a combination of its cancer drug Tagrisso with chemotherapy had gained US approval to treat a particular type of lung cancer.
Read more19 Feb 2024 07:49
LONDON BRIEFING: MoneySupermarket credits Insurance for growth in 2023
(Alliance News) - Stocks in London are set to fall at Monday's open, as concerns over US inflation trends curb risk appetite, and damp hopes of interest rate cuts from the Federal Reserve.
Read more15 Feb 2024 14:44
UK dividends calendar - next 7 days
| Friday 16 February | |
| JPMorgan Asia Growth & Income PLC | dividend payment date |
| JPMorgan Japan Small Cap Growth & Income PLC | dividend payment date |
| Murray International Trust PLC | dividend payment date |
| Premier Miton Group PLC | dividend payment date |
| Schroder Oriental Income Fund | dividend payment date |
| Solid State PLC | dividend payment date |
| Monday 19 February | |
| no events scheduled | |
| Tuesday 20 February | |
| Invesco Bond Income Plus Ltd | |
| Wednesday 21 February | |
| no events scheduled | |
| Thursday 22 February | |
| abrdn Asia Focus PLC | ex-dividend payment date |
| Alumasc Group PLC | ex-dividend payment date |
| AstraZeneca PLC | ex-dividend payment date |
| BlackRock Throgmorton Trust PLC | ex-dividend payment date |
| Braemar PLC | ex-dividend payment date |
| easyJet PLC | ex-dividend payment date |
| Ecofin US Renewables Infrastructure Trust PLC | ex-dividend payment date |
| Endeavour Mining PLC | ex-dividend payment date |
| FRP Advisory Group PLC | ex-dividend payment date |
| Gateley Holdings PLC | ex-dividend payment date |
| GSK PLC | ex-dividend payment date |
| Hercules Site Services PLC | ex-dividend payment date |
| Jersey Electricity PLC | ex-dividend payment date |
| Land Securities Group PLC | ex-dividend payment date |
| Molten Ventures VCT PLC | ex-dividend payment date |
| Northern Bear PLC | ex-dividend payment date |
| Redrow PLC | ex-dividend payment date |
| Samuel Heath & Sons PLC | ex-dividend payment date |
| Titon Holdings PLC | ex-dividend payment date |
| Unilever PLC | ex-dividend payment date |
| Van Elle Holdings PLC | ex-dividend payment date |
| Virgin Money UK PLC | ex-dividend payment date |
| Witan Investment Trust PLC | ex-dividend payment date |
| Comments and questions to newsroom@alliancenews.com | |
| A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional. | |
| Copyright 2024 Alliance News Ltd. All Rights Reserved. | |
13 Feb 2024 16:53
LONDON MARKET CLOSE: Stocks in red amid sticky US inflation data
(Alliance News) - Stock prices in London closed in the red on Tuesday, after a key US inflation reading came in hotter-than-expected.
Read more